Completed PHASE4 INTERVENTIONAL 1-arm NCT01665508

Study to Evaluate Effect of Nebivolol on Angina in Women With Microvascular Disease (NIRVANA)

Nebivolol for the Relief of Microvascular Angina in Women

Sponsor: Forest Laboratories

Interventions Nebivolol

Updated 9 times since 2017 Last updated: Mar 8, 2017 Started: Apr 30, 2013 Primary completion: May 31, 2015 Completion: May 31, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE4 clinical study on Microvascular Angina, this trial is completed. The trial is conducted by Forest Laboratories and has accumulated 9 data snapshots since 2013. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

9 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2023 — Jul 2024 [monthly]

Completed PHASE4
Dec 2022 — Jan 2023 [monthly]

Completed PHASE4
Jan 2021 — Dec 2022 [monthly]

Completed PHASE4

▶ Show 4 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE4
Jun 2017 — Jun 2018 [monthly]

Completed PHASE4
Feb 2017 — Jun 2017 [monthly]

Completed PHASE4
Jan 2017 — Feb 2017 [monthly]

Completed PHASE4

First recorded

Apr 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Forest Laboratories
Massachusetts General Hospital

Data source: Massachusetts General Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Boston, United States